Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00351910
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
- Conditions
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-05-21
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT00347425
- Locations
- 🇺🇸
Site 180, Kenilworth, New Jersey, United States
🇦🇷Site 308, Mendoza, Argentina
🇭🇺Site 212, Gyor, Hungary
Antipsychotic Therapy and First Episode
- Conditions
- First Posted Date
- 2006-06-06
- Last Posted Date
- 2011-02-18
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 169
- Registration Number
- NCT00334035
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 357
- Registration Number
- NCT00330863
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Medical College of Georgia, Department of Psychiatry, Augusta, Georgia, United States
🇺🇸Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center, Fall River, Massachusetts, United States
Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
- Conditions
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00328978
- Locations
- 🇨🇦
Research Site, Saskatoon, Saskatchewan, Canada
Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2008-03-18
- Lead Sponsor
- Khon Kaen University
- Target Recruit Count
- 16
- Registration Number
- NCT00328822
- Locations
- 🇹🇭
Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand
Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study
- Conditions
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00318539
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia
- First Posted Date
- 2006-04-19
- Last Posted Date
- 2017-04-27
- Target Recruit Count
- 20
- Registration Number
- NCT00315900
- Locations
- 🇺🇸
Tuscaloosa VA Medical Center, Tuscaloosa, Alabama, United States
A Study to Evaluate the Efficacy and Safety of Flexible Doses of Extended-release (ER) Paliperidone Compared With Flexible Doses of Quetiapine and Placebo in Patients With Bipolar I Disorder
- Conditions
- Interventions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2014-06-20
- Target Recruit Count
- 493
- Registration Number
- NCT00309699
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
- Conditions
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00302770
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.